Morgan Stanley Uni Qure N.V. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Uni Qure N.V. stock. As of the latest transaction made, Morgan Stanley holds 908,283 shares of QURE stock, worth $58.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

908,283

Previous 603,516 50.5%

Holding current value

$58.1 Million

Previous $6.4 Million 97.92%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$8.34 - $17.27 $2.54 Million - $5.26 Million	304,767 Added 50.5%	908,283 $12.7 Million
Q1 2025 May 15, 2025	SELL	$10.6 - $18.08 $994,364 - $1.7 Million	-93,808 Reduced 13.45%	603,516 $6.4 Million
Q4 2024 Feb 14, 2025	SELL	$4.54 - $17.73 $15,345 - $59,927	-3,380 Reduced 0.48%	697,324 $12.3 Million
Q3 2024 May 14, 2025	SELL	$3.78 - $10.12 $1.57 Million - $4.21 Million	-415,607 Reduced 37.23%	700,704 $3.45 Million
Q3 2024 Nov 14, 2024	SELL	$3.78 - $10.12 $1.57 Million - $4.21 Million	-415,607 Reduced 37.23%	700,704 $3.45 Million
Q2 2024 May 14, 2025	BUY	$4.39 - $5.43 $1.84 Million - $2.28 Million	418,987 Added 60.08%	1,116,311 $5 Million
Q2 2024 Oct 17, 2024	SELL	$4.39 - $5.43 $1.76 Million - $2.18 Million	-401,917 Reduced 26.47%	1,116,311 $5 Million
Q2 2024 Aug 14, 2024	SELL	$4.39 - $5.43 $1.76 Million - $2.18 Million	-401,917 Reduced 26.47%	1,116,311 $5 Million
Q1 2024 Oct 17, 2024	BUY	$4.82 - $6.93 $1.94 Million - $2.79 Million	401,917 Added 36.0%	1,518,228 $7.89 Million
Q1 2024 Aug 16, 2024	SELL	$4.82 - $6.93 $1.16 Million - $1.67 Million	-241,590 Reduced 13.73%	1,518,228 $7.89 Million
Q1 2024 May 15, 2024	SELL	$4.82 - $6.93 $1.16 Million - $1.67 Million	-241,590 Reduced 13.73%	1,518,228 $7.89 Million
Q4 2023 Aug 16, 2024	BUY	$5.63 - $8.27 $3.62 Million - $5.32 Million	643,507 Added 57.65%	1,759,818 $11.9 Million
Q4 2023 Feb 13, 2024	SELL	$5.63 - $8.27 $5.19 Million - $7.62 Million	-921,591 Reduced 34.37%	1,759,818 $11.9 Million
Q3 2023 Nov 15, 2023	BUY	$6.71 - $11.83 $9.49 Million - $16.7 Million	1,413,959 Added 111.56%	2,681,409 $18 Million
Q2 2023 Aug 14, 2023	BUY	$11.12 - $22.2 $914,820 - $1.83 Million	82,268 Added 6.94%	1,267,450 $14.5 Million
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $2.32 Million - $2.86 Million	123,989 Added 11.68%	1,185,182 $23.9 Million
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $1.37 Million - $2.06 Million	75,429 Added 7.65%	1,061,193 $24.1 Million
Q3 2022 Nov 14, 2022	SELL	$16.98 - $25.54 $5.8 Million - $8.72 Million	-341,409 Reduced 25.72%	985,764 $18.5 Million
Q2 2022 Oct 27, 2022	SELL	$13.15 - $20.45 $618,128 - $961,272	-47,006 Reduced 3.42%	1,327,173 $24.7 Million
Q2 2022 Aug 15, 2022	SELL	$13.15 - $20.45 $618,128 - $961,272	-47,006 Reduced 3.42%	1,327,173 $24.7 Million
Q1 2022 Oct 27, 2022	BUY	$14.54 - $21.5 $683,467 - $1.01 Million	47,006 Added 3.54%	1,374,179 $24.8 Million
Q1 2022 May 13, 2022	BUY	$14.54 - $21.5 $1.93 Million - $2.85 Million	132,418 Added 10.66%	1,374,179 $24.8 Million
Q4 2021 Feb 14, 2022	BUY	$20.24 - $36.01 $19.1 Million - $34 Million	944,932 Added 318.34%	1,241,761 $25.8 Million
Q3 2021 Nov 15, 2021	BUY	$26.01 - $38.22 $7.72 Million - $11.3 Million	296,829 New	296,829 $9.5 Million

Others Institutions Holding QURE

# of Institutions

189

Shares Held

51.8M

Call Options Held

4.43M

Put Options Held

1.27M

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $2.99B
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account